Shopping Cart 0
Cart Subtotal
AED 0

Pulmatrix Inc (PULM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Pulmatrix Inc (Pulmatrix), formerly Ruthigen Inc is a clinical stage biopharmaceutical company that develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline product using its proprietary inhaled small particles easily respirable and emitted dry powder delivery technologies. Its pipeline product includes PUR1800, a kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary diseases. Pulmatrix also develops PUR0200, a reformulation of an existing long-acting antimuscarinic agent; and PUR5700, used for the treatment of acute exacerbation of chronic obstructive pulmonary disease, among others. The company also offers clinical trial services. Pulmatrix is headquartered in Lexington, Massachusetts, the US.

Pulmatrix Inc (PULM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pulmatrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Pulmatrix Raises USD 6.5 Million In Extended Series B1 Financing 11

Partnerships 12

Capsugel Enters into Agreement with Pulmatrix 12

Pulmatrix Enters Into Alliance with Celdara Medical 13

Pulmatrix Enters into Co-Development Agreement with Mylan 14

Quotient Clinical Enters Into Agreement With Pulmatrix For PUR0200 15

Pulmatrix Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16

Merger 17

Ruthigen Merges with Pulmatrix 17

Licensing Agreements 18

Vectura Group Enters into Licensing Agreement with Pulmatrix 18

Pulmatrix Enters into Licensing Agreement with RespiVert 19

Oculus Innovative Amends the Licensing Agreement With Ruthigen 20

Equity Offering 22

Pulmatrix Prices Public Offering of Units for USD15.2 Million 22

Pulmatrix Raises USD3.3 Million in Private Placement of Shares 24

Pulmatrix Raises USD5 Million in Private Placement of Shares 25

Pulmatrix Raises USD10 Million in Private Placement of Shares and Warrants 26

Pulmatrix Raises USD0.6 Million in Private Placement of Shares 28

Pulmatrix Raises USD0.9 Million in Private Placement of Shares 29

Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 30

Ruthigen Completes Underwriters Exercise Of Partial Over-Allotment Option Of IPO For USD 20.3 Million 31

Pulmatrix Inc-Key Competitors 33

Pulmatrix Inc-Key Employees 34

Pulmatrix Inc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 36

Financial Announcements 36

May 11, 2018: Pulmatrix Reports Q1 2018 Results 36

Mar 13, 2018: Pulmatrix Announces 2017 Financial Results 37

Nov 09, 2017: Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials 38

Aug 04, 2017: Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials 40

May 05, 2017: Pulmatrix Reports Q1 2017 Financial Results 42

Mar 10, 2017: Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline 43

Corporate Communications 45

Jun 15, 2017: Amit D. Munshi Joins Pulmatrix's Board of Directors 45

May 03, 2017: Pulmatrix Appoints Ted Raad, MBA, as Chief Business Officer 46

Mar 27, 2017: Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board 47

Product News 48

10/30/2017: Pulmatrix Appoints Dr. James Roach as Chief Medical Officer 48

Product Approvals 49

Oct 03, 2017: Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA 49

Jan 17, 2017: Pulmatrix Drug Candidate Receives "Qualified Infectious Disease Product" Designation from the FDA 50

Clinical Trials 51

Oct 31, 2017: Pulmatrix Presents at the North American Cystic Fibrosis Conference 51

Oct 30, 2017: Pulmatrix Provides Update on its Anti-Inflammatory Drug Candidate PUR1800 52

Sep 05, 2017: Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections 53

Other Significant Developments 54

Sep 19, 2017: CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Pulmatrix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pulmatrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pulmatrix Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pulmatrix Raises USD 6.5 Million In Extended Series B1 Financing 11

Capsugel Enters into Agreement with Pulmatrix 12

Pulmatrix Enters Into Alliance with Celdara Medical 13

Pulmatrix Enters into Co-Development Agreement with Mylan 14

Quotient Clinical Enters Into Agreement With Pulmatrix For PUR0200 15

Pulmatrix Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16

Ruthigen Merges with Pulmatrix 17

Vectura Group Enters into Licensing Agreement with Pulmatrix 18

Pulmatrix Enters into Licensing Agreement with RespiVert 19

Oculus Innovative Amends the Licensing Agreement With Ruthigen 20

Pulmatrix Prices Public Offering of Units for USD15.2 Million 22

Pulmatrix Raises USD3.3 Million in Private Placement of Shares 24

Pulmatrix Raises USD5 Million in Private Placement of Shares 25

Pulmatrix Raises USD10 Million in Private Placement of Shares and Warrants 26

Pulmatrix Raises USD0.6 Million in Private Placement of Shares 28

Pulmatrix Raises USD0.9 Million in Private Placement of Shares 29

Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 30

Ruthigen Completes Underwriters Exercise Of Partial Over-Allotment Option Of IPO For USD 20.3 Million 31

Pulmatrix Inc, Key Competitors 33

Pulmatrix Inc, Key Employees 34

Pulmatrix Inc, Subsidiaries 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Pulmatrix Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Pulmatrix Inc (Pulmatrix), formerly Ruthigen Inc is a clinical stage biopharmaceutical company that develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline product using its proprietary inhaled small particles easily respirable and emitted dry powder delivery technologies. Its pipeline product includes PUR1800, a kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary diseases. Pulmatrix also develops PUR0200, a reformulation of an existing long-acting antimuscarinic agent; and PUR5700, used for the treatment of acute exacerbation of chronic obstructive pulmonary disease, among others. The company also offers clinical trial services. Pulmatrix is headquartered in Lexington, Massachusetts, the US.

Pulmatrix Inc (PULM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pulmatrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Pulmatrix Raises USD 6.5 Million In Extended Series B1 Financing 11

Partnerships 12

Capsugel Enters into Agreement with Pulmatrix 12

Pulmatrix Enters Into Alliance with Celdara Medical 13

Pulmatrix Enters into Co-Development Agreement with Mylan 14

Quotient Clinical Enters Into Agreement With Pulmatrix For PUR0200 15

Pulmatrix Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16

Merger 17

Ruthigen Merges with Pulmatrix 17

Licensing Agreements 18

Vectura Group Enters into Licensing Agreement with Pulmatrix 18

Pulmatrix Enters into Licensing Agreement with RespiVert 19

Oculus Innovative Amends the Licensing Agreement With Ruthigen 20

Equity Offering 22

Pulmatrix Prices Public Offering of Units for USD15.2 Million 22

Pulmatrix Raises USD3.3 Million in Private Placement of Shares 24

Pulmatrix Raises USD5 Million in Private Placement of Shares 25

Pulmatrix Raises USD10 Million in Private Placement of Shares and Warrants 26

Pulmatrix Raises USD0.6 Million in Private Placement of Shares 28

Pulmatrix Raises USD0.9 Million in Private Placement of Shares 29

Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 30

Ruthigen Completes Underwriters Exercise Of Partial Over-Allotment Option Of IPO For USD 20.3 Million 31

Pulmatrix Inc-Key Competitors 33

Pulmatrix Inc-Key Employees 34

Pulmatrix Inc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 36

Financial Announcements 36

May 11, 2018: Pulmatrix Reports Q1 2018 Results 36

Mar 13, 2018: Pulmatrix Announces 2017 Financial Results 37

Nov 09, 2017: Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials 38

Aug 04, 2017: Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials 40

May 05, 2017: Pulmatrix Reports Q1 2017 Financial Results 42

Mar 10, 2017: Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline 43

Corporate Communications 45

Jun 15, 2017: Amit D. Munshi Joins Pulmatrix's Board of Directors 45

May 03, 2017: Pulmatrix Appoints Ted Raad, MBA, as Chief Business Officer 46

Mar 27, 2017: Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board 47

Product News 48

10/30/2017: Pulmatrix Appoints Dr. James Roach as Chief Medical Officer 48

Product Approvals 49

Oct 03, 2017: Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA 49

Jan 17, 2017: Pulmatrix Drug Candidate Receives "Qualified Infectious Disease Product" Designation from the FDA 50

Clinical Trials 51

Oct 31, 2017: Pulmatrix Presents at the North American Cystic Fibrosis Conference 51

Oct 30, 2017: Pulmatrix Provides Update on its Anti-Inflammatory Drug Candidate PUR1800 52

Sep 05, 2017: Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections 53

Other Significant Developments 54

Sep 19, 2017: CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Pulmatrix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pulmatrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pulmatrix Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Pulmatrix Raises USD 6.5 Million In Extended Series B1 Financing 11

Capsugel Enters into Agreement with Pulmatrix 12

Pulmatrix Enters Into Alliance with Celdara Medical 13

Pulmatrix Enters into Co-Development Agreement with Mylan 14

Quotient Clinical Enters Into Agreement With Pulmatrix For PUR0200 15

Pulmatrix Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16

Ruthigen Merges with Pulmatrix 17

Vectura Group Enters into Licensing Agreement with Pulmatrix 18

Pulmatrix Enters into Licensing Agreement with RespiVert 19

Oculus Innovative Amends the Licensing Agreement With Ruthigen 20

Pulmatrix Prices Public Offering of Units for USD15.2 Million 22

Pulmatrix Raises USD3.3 Million in Private Placement of Shares 24

Pulmatrix Raises USD5 Million in Private Placement of Shares 25

Pulmatrix Raises USD10 Million in Private Placement of Shares and Warrants 26

Pulmatrix Raises USD0.6 Million in Private Placement of Shares 28

Pulmatrix Raises USD0.9 Million in Private Placement of Shares 29

Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 30

Ruthigen Completes Underwriters Exercise Of Partial Over-Allotment Option Of IPO For USD 20.3 Million 31

Pulmatrix Inc, Key Competitors 33

Pulmatrix Inc, Key Employees 34

Pulmatrix Inc, Subsidiaries 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Pulmatrix Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.